Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
Abrin is an extremely toxic toxalbumin found in the seeds of the rosary pea (or jequirity pea), Abrus precatorius. It has a median lethal dose of 0.7 micrograms per kilogram of body mass when given to mice intravenously (approximately 31.4 times more toxic than ricin, being 22 micrograms per kilogram). The median toxic dose for humans ranges from 10 to 1000 micrograms per kilogram when ingested and is 3.3 micrograms per kilogram when inhaled.
Abrin is a ribosome inhibiting protein like ricin, a toxin which can be found in the seeds of the castor oil plant, and pulchellin, a toxin which can be found in the seeds of Abrus pulchellus. Abrin is classed as a "select agent" under U.S. law.
Abrin is only formed in nature by the rosary pea. The brightly coloured seeds of this plant contain about 0.08% of abrin. The toxin is found within the seeds and its release is prevented by the seed coat. If the seed coat is injured or destroyed (by chewing, for example) the toxin may be released.
Abrin is a water-soluble lectin. Abrin in powdered form is yellowish-white. It is a stable substance and can withstand extreme environmental conditions. Though it is combustible, it does not polymerize easily and is not particularly volatile.
Chemically, abrin is a mixture of four isotoxins, these being abrin-a (Abrus precatorius ( ; AAG) is also included as the fifth protein under the collective name 'abrin'.), -b ( ), -c ( ), and -d ( ). Occasionally, the non-toxic hemagglutinin of
Abrin-a is the most potent of the four isotoxins, encoded for by an intron-free gene, and consists of two subunits or chains, A and B. The primary product of protein biosynthesis, preproabrin, consists of a signal peptide sequence, the amino acid sequences for subunits A and B, and a linker. A molecule of abrin-a has a total of 528 amino acids and is about 65 kDa in mass. Abrin-a is formed after the cleavage of a signal peptide sequence and post-translational modifications such as glycosylation and disulfide bridge formation in the endoplasmic reticulum (ER). The other three abrins, as well as the agglutinin, have a similar structure.
Abrin is not known to have been weaponised, however, due to its high toxicity and the possibility of being processed into an aerosol, the use of abrin as a biological weapon is possible in principle. Despite this, the rosary pea yields small quantities of abrin, which reduces the risk.
Abrin naturally occurs in the seeds of the rosary pea, a plant common to tropical regions that is occasionally employed as an herbal remedy for certain conditions. While the outer shell of the seed protects its contents from the stomachs of most mammals, the seed coats are occasionally punctured to make beaded jewelry. This can lead to poisoning if a seed is swallowed, or if such jewelry is worn against damaged skin. Abrin has been shown to act as an immunoadjuvant in the treatment of cancer in mice.
Although there is no consensus on the level of lethal dose in humans after oral intake, it is assumed that the intake of 0.1 to 1 microgram per kilogram of body weight, or the consumption of a single seed of the rosary pea, may be fatal, but this information is not sufficiently documented. According to other estimates, the LD50 value of abrin is between 10 and 1000 μg/kg and is comparable to that of ricin. The severity of the effects of abrin poisoning vary on the means of exposure to the substance (whether inhaled, ingested, or injected). Exposure to abrin on the skin can cause an allergic reaction, indicated by blisters, redness, irritation, and pain, however, there is no evidence of toxicity after skin contact has been made.
Abrin is significantly more toxic following intravenous administration. The LD50 values obtained vary between 0.03 and 0.06 μg/kg in rabbits and between 1.25 and 1.3 μg/kg in dogs, depending on the species. In clinical studies involving cancer patients, up to 0.3 μg/kg intravenous of abrin immunotoxin was tolerated without the development of serious symptoms of toxicity.
The toxicity of abrin is also increased if it is inhaled. In rats, the LD50 for this route of administration is 3.3 μg/kg.
Abrin resembles ricin in that it is also a type 2 ribosome-inactivating protein (RIP-II) and has a similar mode of action, but abrin's effect is more potent than ricin's. The toxic effect of abrin is due to an intracellular, multi-step process. Abrin works by binding to and penetrating the cells of the body, inhibiting cell protein synthesis after being transported to the endoplasmic reticulum (ER). By attaching its non-specifically binding B chain, which acts as a haptomer, to the carbohydrate chain of a glycoprotein on the cell surface, the abrin molecule anchors itself to the cell, and is subsequently engulfed, however, both specific and nonspecific binding result in the uptake of abrin via endocytosis, as well as the activation of the A chain, caused by the cleavage of the B chain. The activated A chain of abrin, the effectomer, then enters the inner parts of the cell, where it cleaves an adenine (A4324) nucleobase from the 28S rRNA of the large ribosomal subunit of a ribosome on or near the ER, inhibiting the regular process of cellular protein synthesis. Without these proteins, cells cannot survive. This is harmful to the human body and can be fatal even in small exposures. Additionally, abrin may also bind to cells specifically bearing the mannose receptor on their cell surface, since this receptor is found in a particularly high density on cells of the reticulohistiocytic system, the system that is affected in particular by the toxicity of abrin.
Information dealing with the toxicokinetics of abrin is limited and is also disagreed upon. Due to its biochemical properties and its similarity to ricin, it is believed that abrin is at least partially degraded in the gastrointestinal tract. The size of the molecule also restricts absorption through the gastrointestinal tract. Nevertheless, the numerous deaths caused from consuming rosary pea seeds confirm that at least a small portion of the toxin can be absorbed into the systemic circulation via the gastrointestinal tract.
Animal studies on mice show that there is an accumulation of abrin, after injection, in the liver, kidneys, spleen, blood cells, lungs and heart. The molecule is excreted via the kidneys in urine after it undergoes proteolytic cleavage.
Signs and symptoms of abrin exposure
The major symptoms of abrin poisoning depend on the route of exposure and the dose received, though many organs may be affected in severe cases. In general, symptoms can appear anywhere between several hours to several days after exposure. Initial symptoms of abrin poisoning by inhalation may occur within 8 hours of exposure but a more typical time course is 18–24 hours; they can prove fatal within 36–72 hours. Following ingestion of abrin, initial symptoms usually occur rapidly, but can take up to five days to appear.
The later signs and symptoms of exposure are caused by abrin's cytotoxic effects, killing cells in the kidney, liver, adrenal glands, and central nervous system.
Within a few hours of inhaling abrin, common symptoms include fever, cough, airway irritation, chest tightness, pulmonary edema (excess fluid accumulated in the lungs), and nausea. This makes breathing difficult (called dyspnea), and the skin might turn blue or black in a condition called cyanosis, which is a symptom of hypoxia. Excess fluid in the lungs can be diagnosed by x-ray or by listening to the chest with a stethoscope. As the effects of abrin progress, a person can become diaphoretic (sweating heavily) and fluid can build up further. Their blood pressure may drop dramatically, keeping oxygen from reaching the brain and other vital organs in a condition called shock, and respiratory failure may occur, which can be fatal within 36 to 72 hours. If an exposure to abrin by inhalation is not fatal, the airway can become sensitized or irritated.
Swallowing any amount of abrin can lead to severe symptoms. Early symptoms include nausea, vomiting, pain in the mouth, throat, and esophagus, diarrhea, dysphagia (trouble swallowing), and abdominal cramps and pain. As the symptoms progress, bleeding and inflammation begins in the gastrointestinal tract. The affected person can vomit up blood (hematemesis), have blood in their feces, which creates a black, tarry stool called melena, and more internal bleeding. Loss of blood volume and water from nausea, vomiting, diarrhea, and bleeding causes blood pressure to drop and organ damage to begin, which can be seen as the person begins to have somnolence/drowsiness, hematuria (blood in the urine), stupor, convulsions, polydipsia (excessive thirst), and oliguria (low urine production). This ultimately results in multi-system organ failure, hypovolemic shock, vascular collapse, and death.
Abrin can be absorbed through broken skin or absorbed through the skin if dissolved in certain solvents. It can also be injected in small pellets and absorbed through contact with the eyes. Abrin in the powder or mist form can cause redness and pain in the eyes (i.e. conjunctivitis) in small doses. Small doses absorbed through the eyes can also cause tearing (lacrimation). Higher doses can cause tissue damage, severe bleeding at the back of the eye (retinal hemorrhage), and vision impairment or blindness. A large enough dose can be absorbed into the bloodstream and lead to systemic toxicity.
Because no antidote exists for abrin, the most important factor is avoiding abrin exposure in the first place. If exposure cannot be avoided, the most important factor is then getting the abrin off or out of the body as quickly as possible. Abrin exposure can be prevented when it is present in large quantities by wearing appropriate personal protective equipment. Abrin poisoning is treated with supportive care to minimize the effects of the poisoning. This care varies based on the route of exposure and the time since exposure. For recent ingestion, administration of activated charcoal and gastric lavage are both options. Using an emetic (vomiting agent) is not a useful treatment. In cases of eye exposure, flushing the eye with saline helps to remove abrin. Oxygen therapy, airway management, assisted ventilation, monitoring, IV fluid administration, and electrolyte replacement are also important components of treatment.
- Gill DM (1982). "Bacterial toxins: a table of lethal amounts". Microbiological Reviews. 46 (1): 86–94. doi:10.1128/MMBR.46.1.86-94.1982. PMC 373212. PMID 6806598.
- Rudolf C Johnson; et al. (March 2009). "Quantification of L-Abrine in Human and Rat Urine: A Biomarker for the Toxin Abrin". Journal of Analytical Toxicology. 33 (2): 77–84. doi:10.1093/jat/33.2.77. PMID 19239732.
- Dickers KJ, Bradberry SM, Rice P, Griffiths GD, Vale JA (2003). "Abrin poisoning". Toxicological Reviews. 22 (3): 137–42. doi:10.2165/00139709-200322030-00002. PMID 15181663. S2CID 20411255.
- Sadraeian M, Guimaraes GF, Araujo AP, Worthylake DK, LeCour LJ, Pincus SH (2017). "Selective cytotoxicity of a novel immunotoxin based on pulchellin A chain for cells expressing HIV envelope". Scientific Reports. 7 (1): 7579. Bibcode:2017NatSR...7.7579S. doi:10.1038/s41598-017-08037-3. PMC 5548917. PMID 28790381.
- "Facts About Abrin". Centers for Disease Control and Prevention. Archived from the original on 2006-09-28.
- "CDC – The Emergency Response Safety and Health Database: Biotoxin: ABRIN – NIOSH". www.cdc.gov. Retrieved 2015-12-30.
- Dickers, K. J.; Bradberry, S. M.; Rice, P.; Griffiths, G. D.; Vale, J. A. (2003). "Abrin poisoning". Toxicological Reviews. 22 (3): 137–42. doi:10.2165/00139709-200322030-00002. PMID 15181663. S2CID 20411255.
- "Indian Herbs – Rosary Pea".
- Shionoya, H; Arai, H; Koyanagi, N; Ohtake, S; Kobayashi, H; Kodama, T; Kato, H; Tung, TC; Lin, JY (1982). "Induction of antitumor immunity by tumor cells treated with abrin". Cancer Research. 42 (7): 2872–76. PMID 7083176.
- Johnson, R. C.; Zhou, Y.; Jain, R.; Lemire, S. W.; Fox, S.; Sabourin, P.; Barr, J. R. (2009). "Quantification of L-abrine in human and rat urine: a biomarker for the toxin abrin". Journal of Analytical Toxicology. 33 (2): 77–84. doi:10.1093/jat/33.2.77. PMID 19239732.
- Fodstad, O.; Johannessen, J. V.; Schjerven, L.; Pihl, A. (1979). "Toxicity of abrin and ricin in mice and dogs". Journal of Toxicology and Environmental Health. 5 (6): 1073–84. doi:10.1080/15287397909529815. PMID 529341.
- Griffiths GD, Rice P, Allenby AC, et al. (1995). "Inhalation toxicology and histopathology of ricin and abrin toxins". Inhal Toxicol. 7 (2): 269–288. doi:10.3109/08958379509029098.
- Griffiths, G. D.; Lindsay, C. D.; Upshall, D. G. (1994). "Examination of the toxicity of several protein toxins of plant origin using bovine pulmonary endothelial cells". Toxicology. 90 (1–2): 11–27. doi:10.1016/0300-483X(94)90201-1. PMID 8023336.
- Lin, J. Y.; Kao, C. L.; Tung, T. C. (1970). "Study on the effect of tryptic digestion on the toxicity of abrin". Taiwan Yi Xue Hui Za Zhi. Journal of the Formosan Medical Association. 69 (2): 61–3. PMID 5270832.
- Fodstad Ø, Olsnes S, Pihl A (1976). "Toxicity, distribution and elimination of the cancerostatic lectins abrin and ricin after parenteral injection into mice". Br J Cancer. 34 (4): 418–425. doi:10.1038/bjc.1976.187. PMC 2025264. PMID 974006.